Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma

As a condition of accelerated approval, further studies are required
14 Nov 2018
Gastrointestinal cancers;  Cancer Immunology and Immunotherapy

On 9 November 2018, the US Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Approval was based on KEYNOTE 224 (NCT02702414), a single-arm, multicentre trial enrolling 104 patients with hepatocellular carcinoma. Patients were required to have disease progression on or after sorafenib or were intolerant to sorafenib, have measurable disease, and Child-Pugh Class A liver impairment. Twenty-one percent of the patients enrolled were HBV seropositive, 25% were HCV seropositive, and 9 patients (9%) were seropositive for both HBV and HCV. Patients with active autoimmune disease, more than one aetiology of hepatitis, medical conditions requiring immunosuppression, or clinical evidence of ascites by physical exam were ineligible. Patients received pembrolizumab 200 mg as an intravenous infusion every three week until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

The major efficacy outcome measure was confirmed overall response rate, as assessed by independent central review (ICR) according to RECIST v1.1 (modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ). The confirmed ICR-assessed overall response rate was 17% (95% CI: 11, 26), with one complete response and 17 partial responses. Response durations ranged from 3.1 to 16.7 months; 89% of responders had response durations of 6 months or longer and 56% had response durations of 12 months or longer.

Adverse reactions occurring in patients with hepatocellular carcinoma were similar to those described in KEYTRUDA product labelling; however, there were increased incidences of grade 3 or 4 ascites (8%) and immune-mediated hepatitis (2.9%). Grade 3 and 4 laboratory abnormalities that occurred at a higher incidence than in other KEYTRUDA trials were elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).

The recommended pembrolizumab dose for hepatocellular carcinoma is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

Full prescribing information for KEYTRUDA is available here.

FDA granted priority review for this application, which is approved under the provisions of accelerated approval. As a condition of accelerated approval, further studies are required.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System. 

Last update: 14 Nov 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.